Hi Glen. We remain committed to advocating for approval of all treatments that are proven safe and effective based on peer-reviewed data. In phase 2, NurOwn met its primary endpoint for safety but was not powered to assess efficacy. Its phase 3 trial was designed to prove efficacy, but it did not meet its primary and secondary endpoints.